Nền tảng sản xuất tế bào T chỉnh sửa gen đa điểm cho liệu pháp miễn dịch tế bào T nhận dạng "sẵn có"
Tóm tắt
Từ khóa
Tài liệu tham khảo
Porter, 2011, Chimeric antigen receptor therapy for B-cell malignancies, J Cancer, 2, 331, 10.7150/jca.2.331
Riddell, 2013, Chimeric antigen receptor–modified T cells: clinical translation in stem cell transplantation and beyond, Biol Blood Marrow Transplant, 19, S2, 10.1016/j.bbmt.2012.10.021
Kochenderfer, 2009, Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor, J Immunother, 32, 689, 10.1097/CJI.0b013e3181ac6138
Sadelain, 2009, T-cell engineering for cancer immunotherapy, Cancer J, 15, 451, 10.1097/PPO.0b013e3181c51f37
Sadelain, 2009, The promise and potential pitfalls of chimeric antigen receptors, Curr Opin Immunol, 21, 215, 10.1016/j.coi.2009.02.009
Sadelain, 2003, Targeting tumours with genetically enhanced T lymphocytes, Nat Rev Cancer, 3, 35, 10.1038/nrc971
Berger, 2009, Adoptive transfer of virus-specific and tumor-specific T cell immunity, Curr Opin Immunol, 21, 224, 10.1016/j.coi.2009.02.010
Cooper, 2005, T-cell genetic modification for re-directed tumor recognition, Cancer Chemother Biol Response Modif, 22, 293, 10.1016/S0921-4410(04)22014-2
June, 2007, Adoptive T cell therapy for cancer in the clinic, J Clin Invest, 117, 1466, 10.1172/JCI32446
Brenner, 2010, Adoptive T cell therapy of cancer, Curr Opin Immunol, 22, 251, 10.1016/j.coi.2010.01.020
Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma, Nat Med, 14, 1264, 10.1038/nm.1882
Brentjens, 2013, CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med, 5, 177ra38, 10.1126/scitranslmed.3005930
Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842
Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134
Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849
Kowolik, 2006, CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells, Cancer Res, 66, 10995, 10.1158/0008-5472.CAN-06-0160
Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, 371, 1507, 10.1056/NEJMoa1407222
Lee, 2014, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3
Imai, 2004, Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia, Leukemia, 18, 676, 10.1038/sj.leu.2403302
Kügler, 2009, Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework, Protein Eng Des Sel, 22, 135, 10.1093/protein/gzn079
Cermak, 2011, Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting, Nucleic Acids Res, 39, e82, 10.1093/nar/gkr218
Doyle, 2012, TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction, Nucleic Acids Res, 40, W117, 10.1093/nar/gks608
Bogdanove, 2011, TAL effectors: customizable proteins for DNA targeting, Science, 333, 1843, 10.1126/science.1204094
Reyon, 2012, FLASH assembly of TALENs for high-throughput genome editing, Nat Biotechnol, 30, 460, 10.1038/nbt.2170
Joung, 2013, TALENs: a widely applicable technology for targeted genome editing, Nat Rev Mol Cell Biol, 14, 49, 10.1038/nrm3486
Mussolino, 2011, A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity, Nucleic Acids Res, 39, 9283, 10.1093/nar/gkr597
Hudecek, 2010, The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor, Blood, 116, 4532, 10.1182/blood-2010-05-283309
Juillerat, 2014, Comprehensive analysis of the specificity of transcription activator-like effector nucleases, Nucleic Acids Res, 42, 5390, 10.1093/nar/gku155
Betts, 2003, Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation, J Immunol Methods, 281, 65, 10.1016/S0022-1759(03)00265-5
Sander, 2013, In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites, Nucleic Acids Res, 41, e181, 10.1093/nar/gkt716
Pattanayak, 2013, High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity, Nat Biotechnol, 31, 839, 10.1038/nbt.2673
Cradick, 2013, CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity, Nucleic Acids Res, 41, 9584, 10.1093/nar/gkt714
Ran, 2013, Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity, Cell, 154, 1380, 10.1016/j.cell.2013.08.021
Torikai, 2012, A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR, Blood, 119, 5697, 10.1182/blood-2012-01-405365
Torikai, 2013, Toward eliminating HLA class I expression to generate universal cells from allogeneic donors, Blood, 122, 1341, 10.1182/blood-2013-03-478255
Provasi, 2012, Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer, Nat Med, 18, 807, 10.1038/nm.2700
Delgado, 2008, The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia, Biol Blood Marrow Transplant, 14, 1288, 10.1016/j.bbmt.2008.09.001
Simpson, 2003, T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation, BioDrugs, 17, 147, 10.2165/00063030-200317030-00001
Bunjes, 2000, T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999, Transfus Sci, 23, 151, 10.1016/S0955-3886(00)00079-5
Morris, 2003, Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications, Blood, 102, 404, 10.1182/blood-2002-09-2687
Wadhwa, 2006, Infectious complications of chronic lymphocytic leukemia, Semin Oncol, 33, 240, 10.1053/j.seminoncol.2005.12.013
Kochenderfer, 2015, Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor, J Clin Oncol, 33, 540, 10.1200/JCO.2014.56.2025
Hacke, 2012, Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow, Exp Hematol, 40, 3, 10.1016/j.exphem.2011.09.009
Nirschl, 2013, Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy, Clin Cancer Res, 19, 4917, 10.1158/1078-0432.CCR-12-1972